Literature DB >> 22472588

Urologic oncology: Poor trial accrual hinders germ cell tumor therapy advances.

Michael V Williams, Danish Mazhar.   

Abstract

Entities:  

Mesh：

Year:  2012        PMID： 22472588     DOI： 10.1038/nrurol.2012.59

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  False-positive results in clinical trials: multiple significance tests and the problem of unreported comparisons.

Authors:  I F Tannock
Journal:  J Natl Cancer Inst       Date:  1996-02-21       Impact factor: 13.506

2.  A randomized phase III study comparing standard dose BEP with sequential high-dose cisplatin, etoposide, and ifosfamide (VIP) plus stem-cell support in males with poor-prognosis germ-cell cancer. An intergroup study of EORTC, GTCSG, and Grupo Germinal (EORTC 30974).

Authors:  G Daugaard; I Skoneczna; N Aass; R De Wit; M De Santis; H Dumez; S Marreaud; L Collette; J R G Lluch; C Bokemeyer; H J Schmoll
Journal:  Ann Oncol       Date:  2010-11-08       Impact factor: 32.976

3.  Poor correlation between progression-free and overall survival in modern clinical trials: are composite endpoints the answer?

Authors:  Eitan Amir; Bostjan Seruga; Ryan Kwong; Ian F Tannock; Alberto Ocaña
Journal:  Eur J Cancer       Date:  2011-11-22       Impact factor: 9.162

4.  International Germ Cell Consensus Classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Cancer Collaborative Group.

Authors: 
Journal:  J Clin Oncol       Date:  1997-02       Impact factor: 44.544

5.  Impact of the treating institution on survival of patients with "poor-prognosis" metastatic nonseminoma. European Organization for Research and Treatment of Cancer Genito-Urinary Tract Cancer Collaborative Group and the Medical Research Council Testicular Cancer Working Party.

Authors:  L Collette; R J Sylvester; S P Stenning; S D Fossa; G M Mead; R de Wit; P H de Mulder; N Neymark; E Lallemand; S B Kaye
Journal:  J Natl Cancer Inst       Date:  1999-05-19       Impact factor: 13.506

6.  Phase III randomized trial of conventional-dose chemotherapy with or without high-dose chemotherapy and autologous hematopoietic stem-cell rescue as first-line treatment for patients with poor-prognosis metastatic germ cell tumors.

Authors:  Robert J Motzer; Craig J Nichols; Kim A Margolin; Jennifer Bacik; Paul G Richardson; Nicholas J Vogelzang; Dean F Bajorin; Primo N Lara; Lawrence Einhorn; Madhu Mazumdar; George J Bosl
Journal:  J Clin Oncol       Date:  2007-01-20       Impact factor: 44.544

7.  Treatment of disseminated germ-cell tumors with cisplatin, bleomycin, and either vinblastine or etoposide.

Authors:  S D Williams; R Birch; L H Einhorn; L Irwin; F A Greco; P J Loehrer
Journal:  N Engl J Med       Date:  1987-06-04       Impact factor: 91.245

8.  Accelerated BEP: a phase I trial of dose-dense BEP for intermediate and poor prognosis metastatic germ cell tumour.

Authors:  Y Rimmer; J Chester; J Joffe; D Stark; J Shamash; T Powles; J White; J Wason; D Parashar; G Armstrong; D Mazhar; M V Williams
Journal:  Br J Cancer       Date:  2011-08-16       Impact factor: 7.640

9.  Intensive induction chemotherapy with C-BOP/BEP for intermediate- and poor-risk metastatic germ cell tumours (EORTC trial 30948).

Authors:  S D Fosså; B Paluchowska; A Horwich; G Kaiser; P H M de Mulder; O Koriakine; A T van Oosterom; L de Prijck; L Collette; R de Wit
Journal:  Br J Cancer       Date:  2005-11-28       Impact factor: 7.640

10.  Randomized phase III study comparing paclitaxel-bleomycin, etoposide, and cisplatin (BEP) to standard BEP in intermediate-prognosis germ-cell cancer: intergroup study EORTC 30983.

Authors:  Ronald de Wit; Iwona Skoneczna; Gedske Daugaard; Maria De Santis; August Garin; Nina Aass; Alfred J Witjes; Peter Albers; Jeffery D White; José R Germa-Lluch; Sandrine Marreaud; Laurence Collette
Journal:  J Clin Oncol       Date:  2012-01-23       Impact factor: 44.544
  10 in total
  2 in total

1.  Access to urologists for participation in research: An analysis of NCI's Community Oncology Research Program landscape survey.

Authors:  Shellie D Ellis; Riha Vaidya; Joseph M Unger; Kelly Stratton; Jessie Gills; Peter Van Veldhuizen; Eileen Mederos; Emily V Dressler; Matthew F Hudson; Charles Kamen; Heather B Neuman; Anne E Kazak; Ruth C Carlos; Kathryn E Weaver
Journal:  Contemp Clin Trials Commun       Date:  2022-08-14

2.  Clinical implications of the American Joint Committee on Cancer (AJCC) 8th edition update in seminoma pT1 subclassification.

Authors:  Mário Fontes-Sousa; João Lobo; Helena Magalhães; João Cassis; Mariana Malheiro; Sância Ramos; Rui Henrique; Ana Martins; Maria Joaquina Maurício
Journal:  BMC Urol       Date:  2020-08-20       Impact factor: 2.264
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.